Citation Impact
Citing Papers
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
2012
Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder
2010
Prevalence and risk of violence against children with disabilities: a systematic review and meta-analysis of observational studies
2012 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
2007
Trial of Psilocybin versus Escitalopram for Depression
2021 Standout
Agomelatine versus other antidepressive agents for major depression
2013
No health without mental health
2007 Standout
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?
2007
Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
2012
Treatment and prevention of mental disorders in low-income and middle-income countries
2007
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
2008
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
2010
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
2002
Reduced anterior hippocampal formation volume in hyponatremic schizophrenic patients
2007
Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis
2016 StandoutNature
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function?
2007
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
2004
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Oxidative Stress Hypothesis in Alzheimer's Disease
1997 Standout
Firefighters, critical incidents, and drinking to cope: The adequacy of unit-level performance resources as a source of vulnerability and protection.
2008
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
2009
Antipsychotic agents in the treatment of bipolar mania
2009
Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders
2005
Schizophrenia
2009 Standout
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
2010 Standout
Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain
2007 Standout
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
2006 StandoutNobel
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
What We Know: Findings That Every Theory of Schizophrenia Should Explain
2009
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Resources for mental health: scarcity, inequity, and inefficiency
2007 Standout
The burden of non-communicable diseases in South Africa
2009 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Exercise‐associated hyponatremia: A review
2001
A systematic review of longitudinal outcome studies of first-episode psychosis
2006
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
2005
Bidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatine
2009
Crime Victimization in Adults With Severe Mental Illness
2005
Zinc takes the center stage: its paradoxical role in Alzheimer’s disease
2003
Negative life events and mental health of Chinese medical students: The effect of resilience, personality and social support
2012
Twelve-month treatment of psychiatric disorders in the South African Stress and Health Study (World Mental Health Survey Initiative)
2008
Repertoire of microglial and macrophage responses after spinal cord injury
2011 Standout
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
Burden and consequences of child maltreatment in high-income countries
2008 Standout
Omega-3 fatty acids and neuropsychiatric disorders
2005
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Aluminum: Impacts and Disease
2002
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
2013 Standout
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
2002 Standout
Prevalence of Depression During Pregnancy: Systematic Review
2004 Standout
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
2003
Novelty and Anxiolytic Drugs Dissociate Two Components of Hippocampal Theta in Behaving Rats
2013 StandoutNobel
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Fish Intake, Contaminants, and Human Health
2006 Standout
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Rethinking schizophrenia
2010 StandoutNature
The psychological impact of the COVID-19 epidemic on college students in China
2020 Standout
Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients
2003
Fluoride in drinking water and its removal
2006 Standout
Environment and Schizophrenia: Environmental Factors in Schizophrenia: Childhood Trauma--A Critical Review
2006
Depression in adolescence
2012 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Mental health literacy: Empowering the community to take action for better mental health.
2011 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study
2009
Functional organization of the hippocampal longitudinal axis
2014 StandoutNobel
Alzheimer's Disease
2010 Standout
Mental health of young people: a global public-health challenge
2007 Standout
The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes
2004
Very long-chainn-3 fatty acids and human health: fact, fiction and the future
2017
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches
2001
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders
2012
Child development: risk factors for adverse outcomes in developing countries
2007 Standout
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1999
Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
2001
Restoring invisible and abandoned trials: a call for people to publish the findings
2013
Cumulative Traumas and Psychosis: an Analysis of the National Comorbidity Survey and the British Psychiatric Morbidity Survey
2007
Omega-3 Fatty Acids Improve Recovery, whereas Omega-6 Fatty Acids Worsen Outcome, after Spinal Cord Injury in the Adult Rat
2006
The variable nature of cognitive control: a dual mechanisms framework
2012 Standout
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
2004
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
2008
Anterior Medial Temporal Lobe Volumes in Polydipsic Schizophrenic Patients with and without Hypo-Osmolemia: A Pilot Study
1997
Review of Child and Adolescent Refugee Mental Health
2004
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
2020
Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review
2008
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Large-scale brain networks and psychopathology: a unifying triple network model
2011 Standout
Optimizing mental health services in low-income and middle-income countries
2011
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
New atypical antipsychotics for schizophrenia: iloperidone
2010
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
2012
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
2005
Getting to the “COR”
2014 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The EPPIC Follow-Up Study of First-Episode Psychosis
2010
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
ChatGPT: five priorities for research
2023 StandoutNature
Interventions for enhancing medication adherence
2008 Standout
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
2006
Haloperidol dose for the acute phase of schizophrenia
2013
Pivotal mental states
2020
Oxidative stress in schizophrenia - focusing on the main markers.
2011
Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications
2005
Interventions for enhancing medication adherence
2014 Standout
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability
2012
A systematic review of atypical antipsychotic drugs in schizophrenia
2003
Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia
2001
The Neuroendocrinology of Chronic Fatigue Syndrome
2003
Paliperidone for schizophrenia
2008
Industry sponsorship and research outcome
2017 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of Robin Emsley being referenced
Outcome of first-episode schizophrenia and the new antipsychotics
1996
A new model for the pathophysiology of Alzheimer's disease. Aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin.
1997
The new-generation antipsychotics - integrating the neuropathology and pharmacology of schizophrenia
1999
Comparison of Response to a Selective Serotonin Reuptake Inhibitor in Children, Adolescents, and Adults with Posttraumatic Stress Disorder
2002
Posttraumatic Stress Disorder and Occupational Disability in South African Security Force Members
2003
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
2005
Remission in First-Episode Psychosis
2006
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis
2004
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
2005
A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
2000
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
1999
A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia
2004
Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia
2002
Linking Posttraumatic Stress Disorder and Psychosis
2003
Disordered Water Homeostasis in Schizophrenia and Cerebral Ventricular Size
1995
Depressive and Anxiety Symptoms in Patients With Schizophrenia and Schizophreniform Disorder
1999
Duration of untreated psychosis and outcome in first‐episode psychosis. Perspective from a developing country
2004
The nature of relapse in schizophrenia
2013
Ethnicity and Treatment Response in Schizophrenia
2002
Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial
2005
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
2007
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine
2012
A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone
2009
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
2008
Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia
2003
Pathways to Inpatient Mental Health Care Among People With Schizophrenia Spectrum Disorders in South Africa
2010
Psychometric properties of the Multidimensional Scale of Perceived Social Support in youth
2007
Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates
2004
Evidence-based pharmacotherapy of schizophrenia
2004
Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities
2001
The new and evolving pharmacotherapy of schizophrenia
2003
Incidence of Tardive Dyskinesia in First-Episode Psychosis Patients Treated With Low-Dose Haloperidol
2003
A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
2003
Association between a catechol-o-methyltransferase polymorphism and obsessive–compulsive disorder in the Afrikaner population
2001
Water excretion and plasma vasopressin in psychotic disorders
1989
Pathways to Inpatient Mental Health Care Among People With Schizophrenia Spectrum Disorders in South Africa
2010
Determining the optimal dose of haloperidol in first-episode psychosis
2001
The relationships between depression and remission in first-episode psychosis.
2006
P-4-76 Risperidone in the treatment of first-episode patients with schizophreniform disorder: A double-blind multicenter study
1995
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
2006
Partial response to antipsychotic treatment: the patient with enduring symptoms.
1999
Zinc and platelet membrane microviscosity in Alzheimer's disease. The in vivo effect of zinc on platelet membranes and cognition.
1997
Clinical and biochemical characteristics of collapsed ultramarathon runners
1994
Focus on psychiatry in South Africa
2001